Quick Answer
Kairos Pharma, LTD. reported Net Income of -$5.45 million for fiscal year 2025.
Kairos Pharma, LTD. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$5.45M | -109.3% |
| 2024 | -$2.60M | -43.7% |
| 2023 | -$1.81M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.40M | -33.5% | +1.7% |
| June 30, 2025 | -$1.42M | -462.1% | -12.7% |
| March 31, 2025 | -$1.26M | -290.7% | -20.5% |
| September 30, 2024 | -$1.05M | -235.6% | -313.8% |
| June 30, 2024 | -$253.0K | — | +21.7% |
| March 31, 2024 | -$323.0K | — | -3.5% |
| September 30, 2023 | -$312.0K | — | — |
- Kairos Pharma, LTD. showed a decrease of -109.3% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Kairos Pharma, LTD.’s net income has declined by 200.6% (from -$1.81 million to -$5.45 million).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: